Loading...
•
Dec 31, 2023
Relay Therapeutics Q4 2023 Earnings Report
Reported fourth quarter and full year 2023 financial results and corporate highlights.
Key Takeaways
Relay Therapeutics reported its Q4 and full year 2023 financial results, highlighting progress across its portfolio, including advancing multiple clinical programs and investing in its Dynamo platform. The company's cash, cash equivalents, and investments totaled approximately $750 million at the end of Q4 2023, expected to fund operations into the second half of 2026.
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort.
Initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg.
Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer.
Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026.
Forward Guidance
Relay Therapeutics anticipates several milestones in 2024, including RLY-2608 data updates, initial safety data for RLY-2608 in combination with fulvestrant and ribociclib, a lirafugratinib tumor agnostic data and regulatory update, and the disclosure of new pre-clinical programs.
Positive Outlook
- RLY-2608 + fulvestrant data update in the second half of 2024
- RLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024
- Lirafugratinib: tumor agnostic data and regulatory update in the second half of 2024
- Pre-clinical: disclose new program(s) in 2024
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...